Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

Por Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
Publicado em 2011

Reproducibility of the WHO classification of thymomas: practical implications

Por Zucali, PA, Di Tommaso, L, Petrini, I, Battista, S, Lee, HS, Merino, M, Lorenzi, E, Voulaz, E, De Vincenzo, F, Simonelli, M, Roncalli, M, Giordano, L, Alloisio, M, Santoro, A, Giaccone, G.
Publicado em 2012

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours

Por Zucali, P A, Simonelli, M, De Vincenzo, F, Lorenzi, E, Perrino, M, Bertossi, M, Finotto, R, Naimo, S, Balzarini, L, Bonifacio, C, Timofeeva, I, Rossoni, G, Mazzola, G, Lambiase, A, Bordignon, C, Santoro, A
Publicado em 2013

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Por Ceresoli, G L, Zucali, P A, Mencoboni, M, Botta, M, Grossi, F, Cortinovis, D, Zilembo, N, Ripa, C, Tiseo, M, Favaretto, A G, Soto-Parra, H, De Vincenzo, F, Bruzzone, A, Lorenzi, E, Gianoncelli, L, Ercoli, B, Giordano, L, Santoro, A
Publicado em 2013